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Empyema Thoracis
from Salmonella
Choleraesuis
To the Editor: The clinical pre-
sentations of nontyphoidal
Salmonella infection are protean,
including gastroenteritis (most com-
mon), bacteremia, septic arthritis,
osteomyelitis, and endovascular
infection. (1). Despite the growing
number of patients with invasive
infection due to nontyphoid
Salmonella, reports of thoracic
empyema due to these organisms
remain rare (2–6).
We searched the computer data-
base of our microbiology laboratory
for patients with positive pleural effu-
sion culture from June 1997 to
February 2004. Patients were includ-
ed if they met the following criteria:
1) thoracentesis recovered purulent
pleural fluid; 2) microorganisms iden-
tified by microscopic examination;
and 3) a Salmonella species isolated
from a pleural effusion specimen.
Isolates of Salmonella were identi-
fied to the serotype level, according to
the Kauffman and White scheme,
using somatic and flagellar antigens
(Denka Seiken Co., Ltd., Tokyo,
Japan) and also by conventional
methods and the Phoenix System
(panel type, NMIC/ID4) (Becton
Dickson, Sparks, MD, USA) (7).
Susceptibilities of Salmonella isolates
to ampicillin, cefotaxime, chloram-
phenicol, ciprofloxacin, and trimetho-
prim-sulfamethoxazole were deter-
mined by the disk diffusion method.
Organisms were categorized as sus-
ceptible or resistant to the antimicro-
bial agents tested on the basis of
National Committee for Clinical
Laboratory Standards (NCCLS)
guidelines (8). Antimicrobial therapy
was considered to be appropriate
when the antimicrobial agent was
active in vitro by the disk diffusion
susceptibility method against a
Salmonella isolate.
During the study, 973 patients with
a diagnosis of empyema thoracis were
identified; 12 (1.23%) of these
patients, including 9 men and 3
women, were infected with
Salmonella species. The clinical char-
acteristics of the 12 patients are sum-
marized in the online Appendix Table
(available from http://www.cdc.gov/
ncidod/eid/vol11no09/05-0030_
app.htm). The median age was 49
years; 1 patient was >65 years of age.
Underlying diseases were present in
all patients, including 7 with malig-
nancy, 5 with gallstones, and 3 each
with diabetes mellitus and chronic
renal failure. Five patients had used
antacids and 3 patients had received
chemotherapy or steroids. Ten
patients (83.3%) were immunocom-
promised and had a variety of illness-
es, including malignancy, liver cirrho-
sis, and diabetes mellitus. Common
symptoms were dyspnea (83.3%),
fever (75%), and cough (50%).
Analysis of pleural effusion showed a
median leukocyte count of 25,600/µL,
a lactate dehydrogenase level of 513
U/L, and a glucose level of 88 mg/dL.
Gram staining was conducted on 3
patients’ pleural effusion but none of
them showed positive results.
Twenty-three  Salmonella isolates
were recovered as the sole pathogen
from various clinical specimens,
including pleural effusion (15 isolates),
blood (6 isolates), ascites (1 isolate),
and aortic wall (1 isolate). Among the
12 patients with empyema thoracis, 4
had  Salmonella enterica serotype
Typhimurium (S. Typhimurium) and 1
had group C2 Salmonella during
1997–1999; 7 patients had Salmonella
enterica  serotype Choleraesuis
(S. Choleraesuis) after 1998. All S.
Typhimurium and group C2
Salmonella were isolated from pleural
effusion specimens, but S.
Choleraesuis was isolated from multi-
ple extrapulmonary sites including
blood, ascites, and aortic wall (Online
Table). Although the number of study
cases is limited, it may suggest that S.
Choleraesuis is more invasive than 2
other Salmonella species. 
Among the S. Choleraesuis iso-
lates recovered from 7 patients, 2
were resistant to ampicillin and sul-
famethoxazole-trimethoprim, 3 were
resistant to chloramphenicol, 1 was
resistant to ciprofloxacin, and all were
susceptible to cefotaxime. All S.
Typhimurium isolates were suscepti-
ble to sulfamethoxazole-trimetho-
prim, ciprofloxacin, and cefotaxime.
Two of the 4 patients had isolates that
were resistant to chloramphenicol,
and 2 other patients had isolates that
were resistant to ampicillin. The
group C2 salmonella  isolate was
resistant to chloramphenicol only.
Among the 12 Salmonella isolates
from patients with empyema thoracis,
9 were resistant to >1 commonly used
antimicrobial. Treatment and outcome
information was available for 11 of
the 12 patients. All 11 patients
received antimicrobials drugs (medi-
an duration 35 days); this therapy was
appropriate in 9 of 11 patients. Six
patients had thoracentesis, 2 had close
tube thoracostomy, and 1 had open
drainage. One of the 4 patients with S.
Typhimurium empyema who did not
receive appropriate antimicrobial
drugs died. In contrast, 4 (57%) of the
7 patients with S. Choleraesuis infec-
tion, including 1 who did not receive
appropriate antimicrobial therapy,
died. Another factor related to out-
come was drainage. One (20%) of the
5 patients who underwent tube thora-
costomy or thoracoscopy died, while
3 (50%) of the 6 patients who under-
went thoracentesis died. All 3 of these
patients had S. Choleraesuis.
Most (92%) of our patients were
<65 years of age. These data indicate
that Salmonella should be considered
as a potential cause of thoracic empye-
ma, even in younger patients, especial-
ly in the presence of malignancy or
hepatobiliary disease. More than half
of our patients had used antacids or
had suffered from gallstones. This
finding suggests that susceptibility to
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Salmonella infection may be increased
by alterations in the gastrointestinal
tract, including decreased gastric acid-
ity and chronic gastrointestinal dis-
ease. Leukocytosis was noted in 25%
of patients. In fact, two thirds of the
patients had a normal leukocyte count
with immature leukocytes, which may
be attributable to their relatively
impaired cell-mediated immunity.
The predominant organism in this
series was S. Choleraesuis, followed
by  S.  Typhimurium. In Taiwan, the
rate of resistance of S. Choleraesuis to
ampicillin, chloramphenicol, or sul-
famethoxazole-trimethoprim increased
to approximately 90% for all 3 drugs
and the rate of resistance to
ciprofloxacin was from 7.7% to 59%
(5–7). The resistance rate of S.
Choleraesuis to ciprofloxacin in this
study was similar to our previous
report (7). 
Nine of the 11 patients who com-
pleted follow-up information received
appropriate antimicrobial drugs with
drainage; however, 4 died. These 4
deaths (57%) were due to S.
Choleraesuis-related empyema; 3
patients had underlying malignancy.
Although appropriate antimicrobial
drugs were used, our data suggest that
more aggressive treatment with open
drainage of the pleural effusion might
have contributed to a better outcome
than closed tube thoracostomy or sim-
ple thoracocentesis alone. In contrast
to  S. Choleraesuis-related infection,
all 4 patients with non–S.
Choleraesuis-related thoracic empye-
ma survived. One of these patients did
not receive appropriate antimicrobial
drug treatment, but did have adequate
drainage with simple thoracocentesis.
This suggests adequate and aggres-
sive drainage of pleural effusion may
be as important as appropriate antimi-
crobial drugs. However, the overall
death rate (36%) in this study was still
higher than that of other reports (9).
This might have been due to the high
number of immunocompromised
patients in this study.
In conclusion, thoracic empyema
is a rare complication of nontyphoid
Salmonella infection and is closely
associated with an immunocompro-
mised condition, even in patients <65
years of age. Higher rates of resist-
ance and death were noted in patients
with empyema thoracic caused by S.
Choleraesuis. Early diagnosis, appro-
priate antimicrobial drug therapy, and
aggressive drainage are necessary to
improve the outcome of patients with
thoracic empyema due to S.
Choleraesuis.
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Asymptomatic
Yersinia pestis
Infection, China
To the Editor: Plague is one of the
oldest identifiable diseases. Modern
public health measures and effective
antimicrobial treatments have led to a
decrease in plague cases worldwide.
However, plague remains endemic in
many natural foci. Since the early
1990s, the World Health Organization
(WHO) has reported a steadily increas-
ing trend in human plague cases,
which has resulted in the recognition
of plague as a reemerging disease (1).
The emergence of antimicrobial drug–
resistant strains of Yersinia pestis,
along with an increasing number of
plague cases, remind us that plague
still poses a serious public health threat
(2,3). In China, human cases of plague
have been reported to WHO nearly
every year from 1989 to 2003; these
account for 9.5% of cases and 15.5%
of deaths from this disease in Asia (1).
Human cases of plague in China are
usually caused by contact with plague-
infected rodents. Here, we report the
results of a serologic survey by using 3
methods (passive hemagglutination
assay, Western blot, and protein
microarray analysis) in marmot
hunters in Qinghai Province, China.
One hundred twenty serum sam-
ples were collected in 2 villages in
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